{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:21:58Z","timestamp":1792167718169,"version":"4.4.0"},"reference-count":130,"publisher":"Portland Press Ltd.","issue":"6","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,9,1]]},"abstract":"<jats:p>Aldosterone concentrations are inappropriately high in many patients with hypertension, as well as in an increasing number of individuals with metabolic syndrome and sleep apnoea. A growing body of evidence suggests that aldosterone and\/or activation of the MR (mineralocorticoid receptor) contributes to cardiovascular remodelling and renal injury in these conditions. In addition to causing sodium retention and increased blood pressure, MR activation induces oxidative stress, endothelial dysfunction, inflammation and subsequent fibrosis. The MR may be activated by aldosterone and cortisol or via transactivation by the AT1 (angiotenin II type\u00a01) receptor through a mechanism involving the EGFR (epidermal growth factor receptor) and MAPK (mitogen-activated protein kinase) pathway. In addition, aldosterone can generate rapid non-genomic effects in the heart and vasculature. MR antagonism reduces mortality in patients with CHF (congestive heart failure) and following myocardial infarction. MR antagonism improves endothelial function in patients with CHF, reduces circulating biomarkers of cardiac fibrosis in CHF or following myocardial infarction, reduces blood pressure in resistant hypertension and decreases albuminuria in hypertensive and diabetic patients. In contrast, whereas adrenalectomy improves glucose homoeostasis in hyperaldosteronism, MR antagonism may worsen glucose homoeostasis and impairs endothelial function in diabetes, suggesting a possible detrimental effect of aldosterone via non-genomic pathways.<\/jats:p>","DOI":"10.1042\/cs20070123","type":"journal-article","created":{"date-parts":[[2007,8,14]],"date-time":"2007-08-14T04:40:39Z","timestamp":1187066439000},"page":"267-278","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":199,"title":["Aldosterone and end-organ damage"],"prefix":"10.1042","volume":"113","author":[{"given":"Annis\u00a0M.","family":"Marney","sequence":"first","affiliation":[{"name":"Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Vanderbilt University Medical Center, 550 Robinson Research Building, Nashville, TN 37232-6602, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy\u00a0J.","family":"Brown","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Vanderbilt University Medical Center, 550 Robinson Research Building, Nashville, TN 37232-6602, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2007,8,13]]},"reference":[{"key":"2021120120460888400_B1","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1006\/bbrc.1995.2464","article-title":"Ligand-induced conformational changes in the mineralocorticoid receptor analyzed by protease mapping","volume":"215","author":"Trapp","year":"1995","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021120120460888400_B2","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1073\/pnas.95.6.2973","article-title":"Subcellular localization of mineralocorticoid receptors in living cells: effects of receptor agonists and antagonists","volume":"95","author":"Fejes-Toth","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021120120460888400_B3","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1210\/endo.142.4.8095","article-title":"The serum- and glucocorticoid-induced kinase is a physiological mediator of aldosterone action","volume":"142","author":"Bhargava","year":"2001","journal-title":"Endocrinology"},{"key":"2021120120460888400_B4","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1126\/science.2845584","article-title":"Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated","volume":"242","author":"Funder","year":"1988","journal-title":"Science"},{"key":"2021120120460888400_B5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0022-4731(80)90285-X","article-title":"Evidence for a specific mineralocorticoid receptor in rat pituitary and brain","volume":"12","author":"Moguilewsky","year":"1980","journal-title":"J. Steroid Biochem."},{"key":"2021120120460888400_B6","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1161\/01.RES.71.3.503","article-title":"Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor","volume":"71","author":"Lombes","year":"1992","journal-title":"Circ. Res."},{"key":"2021120120460888400_B7","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/01.HYP.0000255636.11931.a2","article-title":"Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1","volume":"49","author":"Shibata","year":"2007","journal-title":"Hypertension"},{"key":"2021120120460888400_B8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1161\/01.RES.0000080521.15238.E5","article-title":"Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure","volume":"93","author":"Qin","year":"2003","journal-title":"Circ. Res."},{"key":"2021120120460888400_B9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10741-005-2344-2","article-title":"Mineralocorticoid receptors: distribution and activation","volume":"10","author":"Funder","year":"2005","journal-title":"Heart Failure Rev."},{"key":"2021120120460888400_B10","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1073\/pnas.94.9.4440","article-title":"Cloning and characterization of a putative human serine\/threonine protein kinase transcriptionally modified during anisotonic and isotonic alterations of cell volume","volume":"94","author":"Waldegger","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021120120460888400_B11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1749-6632.2001.tb03665.x","article-title":"ENaC subunits are molecular components of the arterial baroreceptor complex","volume":"940","author":"Drummond","year":"2001","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"2021120120460888400_B12","first-page":"97","article-title":"Aldosterone: refreshing a slow hormone by swift action","volume":"19","author":"Boldyreff","year":"2004","journal-title":"News Physiol. Sci."},{"key":"2021120120460888400_B13","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1161\/01.CIR.0000093188.53554.44","article-title":"Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation","volume":"108","author":"Liu","year":"2003","journal-title":"Circulation"},{"key":"2021120120460888400_B14","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1161\/01.RES.0000106135.02935.E1","article-title":"Rapid inhibition of vasoconstriction in renal afferent arterioles by aldosterone","volume":"93","author":"Uhrenholt","year":"2003","journal-title":"Circ. Res."},{"key":"2021120120460888400_B15","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/01.HYP.0000111138.78714.1a","article-title":"Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole","volume":"43","author":"Arima","year":"2004","journal-title":"Hypertension"},{"key":"2021120120460888400_B16","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/01.HYP.0000083298.23119.16","article-title":"Rapid nongenomic effects of aldosterone on human forearm vasculature","volume":"42","author":"Schmidt","year":"2003","journal-title":"Hypertension"},{"key":"2021120120460888400_B17","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1161\/01.HYP.0000205224.58715.cc","article-title":"Rapid nongenomic effects of aldosterone on the renal vasculature in humans","volume":"47","author":"Schmidt","year":"2006","journal-title":"Hypertension"},{"key":"2021120120460888400_B18","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1210\/en.2003-1137","article-title":"Rapid, nongenomic effects of aldosterone in the heart mediated by epsilon protein kinase C","volume":"145","author":"Mihailidou","year":"2004","journal-title":"Endocrinology"},{"key":"2021120120460888400_B19","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1161\/01.HYP.0000205225.88721.2c","article-title":"Nongenomic renal effects of aldosterone: dependency on NO and genomic actions","volume":"47","author":"Chun","year":"2006","journal-title":"Hypertension"},{"key":"2021120120460888400_B20","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1210\/en.2004-1130","article-title":"Eplerenone blocks nongenomic effects of aldosterone on the Na+\/H+ exchanger, intracellular Ca2+ levels, and vasoconstriction in mesenteric resistance vessels","volume":"146","author":"Michea","year":"2005","journal-title":"Endocrinology"},{"key":"2021120120460888400_B21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/1570161043476447","article-title":"Endothelial dysfunction in heart failure: mechanisms and therapeutic approaches","volume":"2","author":"Bauersachs","year":"2004","journal-title":"Curr. Vasc. Pharmacol."},{"key":"2021120120460888400_B22","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1161\/01.HYP.0000118519.66430.22","article-title":"Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone\/salt-induced hypertensive rats","volume":"43","author":"Nishiyama","year":"2004","journal-title":"Hypertension"},{"key":"2021120120460888400_B23","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0895-7061(04)00811-8","article-title":"Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction with the renin-angiotensin system","volume":"17","author":"Iglarz","year":"2004","journal-title":"Am. J. Hypertens."},{"key":"2021120120460888400_B24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/01.HYP.0000171479.36880.17","article-title":"Participation of prostacyclin in endothelial dysfunction induced by aldosterone in normotensive and hypertensive rats","volume":"46","author":"Blanco-Rivero","year":"2005","journal-title":"Hypertension"},{"key":"2021120120460888400_B25","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1210\/jc.2003-031545","article-title":"Effect of aldosterone and glycyrrhetinic acid on the protein expression of PAI-1 and p22pbox in human mononuclear leukocytes","volume":"89","author":"Calo","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021120120460888400_B26","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1210\/en.2006-1157","article-title":"Angiotensin II receptor type\u00a01-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system","volume":"148","author":"Hirono","year":"2007","journal-title":"Endocrinology"},{"key":"2021120120460888400_B27","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1161\/01.HYP.0000226054.53527.bb","article-title":"Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity","volume":"48","author":"Nagata","year":"2006","journal-title":"Hypertension"},{"key":"2021120120460888400_B28","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nm1545","article-title":"Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity","volume":"13","author":"Leopold","year":"2007","journal-title":"Nat. Med."},{"key":"2021120120460888400_B29","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1161\/01.HYP.21.6.929","article-title":"Vasodilation to acetylcholine in primary and secondary forms of human hypertension","volume":"21","author":"Taddei","year":"1993","journal-title":"Hypertension"},{"key":"2021120120460888400_B30","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1161\/01.CIR.0000129307.26791.8E","article-title":"Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism","volume":"109","author":"Nishizaka","year":"2004","journal-title":"Circulation"},{"key":"2021120120460888400_B31","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1042\/cs1030425","article-title":"Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy","volume":"103","author":"Farquharson","year":"2002","journal-title":"Clin. Sci."},{"key":"2021120120460888400_B32","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0021-9150(02)00363-5","article-title":"Aldosterone induces contraction of the resistance arteries in man","volume":"166","author":"Romagni","year":"2003","journal-title":"Atherosclerosis"},{"key":"2021120120460888400_B33","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","article-title":"Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure","volume":"101","author":"Farquharson","year":"2000","journal-title":"Circulation"},{"key":"2021120120460888400_B34","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s00125-004-1510-8","article-title":"Spironolactone impairs endothelial function and heart rate variability in patients with Type\u00a02 diabetes","volume":"47","author":"Davies","year":"2004","journal-title":"Diabetologia"},{"key":"2021120120460888400_B35","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1161\/01.HYP.33.4.981","article-title":"Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis","volume":"33","author":"Robert","year":"1999","journal-title":"Hypertension"},{"key":"2021120120460888400_B36","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1161\/01.CIR.104.2.137","article-title":"Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes","volume":"104","author":"Harada","year":"2001","journal-title":"Circulation"},{"key":"2021120120460888400_B37","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1161\/01.RES.0000159937.05502.d1","article-title":"Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells","volume":"96","author":"Jaffe","year":"2005","journal-title":"Circ. Res."},{"key":"2021120120460888400_B38","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1161\/01.RES.0000180753.63183.95","article-title":"Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells","volume":"97","author":"Min","year":"2005","journal-title":"Circ. Res."},{"key":"2021120120460888400_B39","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1161\/01.HYP.37.2.787","article-title":"Mineralocorticoid receptor affects AP-1 and nuclear factor-\u03baB activation in angiotensin II-induced cardiac injury","volume":"37","author":"Fiebeler","year":"2001","journal-title":"Hypertension"},{"key":"2021120120460888400_B40","first-page":"514","article-title":"Aldosterone synthase inhibitor FAD286 ameliorates angiotensin II-induced end-organ damage","volume":"44","author":"Fiebeler","year":"2004","journal-title":"Hypertension"},{"key":"2021120120460888400_B41","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1161\/01.HYP.0000248135.97380.76","article-title":"Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism","volume":"48","author":"Luther","year":"2006","journal-title":"Hypertension"},{"key":"2021120120460888400_B42","first-page":"893","article-title":"Mineralocorticoid excess, dietary sodium, and myocardial fibrosis","volume":"120","author":"Brilla","year":"1992","journal-title":"J. Lab. Clin. Med."},{"key":"2021120120460888400_B43","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","article-title":"Aldosterone: a mediator of myocardial necrosis and renal arteriopathy","volume":"141","author":"Rocha","year":"2000","journal-title":"Endocrinology"},{"key":"2021120120460888400_B44","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.lab.2003.07.004","article-title":"Tissue angiotensin II in the regulation of inflammatory and fibrogenic components of repair in the rat heart","volume":"143","author":"Sun","year":"2004","journal-title":"J. Lab. Clin. Med."},{"key":"2021120120460888400_B45","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1210\/en.2002-220120","article-title":"Selective aldosterone blockade prevents angiotensin II\/salt-induced vascular inflammation in the rat heart","volume":"143","author":"Rocha","year":"2002","journal-title":"Endocrinology"},{"key":"2021120120460888400_B46","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1161\/01.ATV.17.6.1152","article-title":"Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats","volume":"17","author":"Benetos","year":"1997","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021120120460888400_B47","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1161\/01.CIR.0000039328.33137.6C","article-title":"Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone","volume":"106","author":"Lacolley","year":"2002","journal-title":"Circulation"},{"key":"2021120120460888400_B48","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1139\/y05-068","article-title":"Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy","volume":"83","author":"Neves","year":"2005","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"2021120120460888400_B49","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1172\/JCI118867","article-title":"Role of aldosterone in the remnant kidney model in the rat","volume":"98","author":"Greene","year":"1996","journal-title":"J. Clin. Invest."},{"key":"2021120120460888400_B50","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/01.HYP.31.1.451","article-title":"Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats","volume":"31","author":"Rocha","year":"1998","journal-title":"Hypertension"},{"key":"2021120120460888400_B51","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1046\/j.1523-1755.2000.00277.x","article-title":"Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo","volume":"58","author":"Brown","year":"2000","journal-title":"Kidney Int."},{"key":"2021120120460888400_B52","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1681\/ASN.2005111196","article-title":"Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type\u00a02 diabetic rats","volume":"17","author":"Han","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021120120460888400_B53","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1161\/hyp.39.2.614","article-title":"Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading","volume":"39","author":"Martinez","year":"2002","journal-title":"Hypertension"},{"key":"2021120120460888400_B54","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/01.CIR.0000151516.84238.37","article-title":"Aldosteronism and a proinflammatory vascular phenotype: role of Mg2+, Ca2+, and H2O2 in peripheral blood mononuclear cells","volume":"111","author":"Ahokas","year":"2005","journal-title":"Circulation"},{"key":"2021120120460888400_B55","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.steroids.2005.02.004","article-title":"Nongenomic effects of mineralocorticoid receptor activation in the cardiovascular system","volume":"70","author":"Mihailidou","year":"2005","journal-title":"Steroids"},{"key":"2021120120460888400_B56","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1081\/CEH-57423","article-title":"Alterations in aldosterone and angiotensin II levels in salt-induced hypertension","volume":"27","author":"Bayorh","year":"2005","journal-title":"Clin. Exp. Hypertens."},{"key":"2021120120460888400_B57","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1291\/hypres.29.169","article-title":"Augmentation of intrarenal angiotensin II levels in uninephrectomized aldosterone\/salt-treated hypertensive rats; renoprotective effects of an ultrahigh dose of olmesartan","volume":"29","author":"Fan","year":"2006","journal-title":"Hypertens. Res."},{"key":"2021120120460888400_B58","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.regpep.2006.11.007","article-title":"Differential sympathetic and angiotensinergic responses in rats submitted to low- or high-salt diet","volume":"140","author":"Carillo","year":"2007","journal-title":"Regul. Pept."},{"key":"2021120120460888400_B59","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1046\/j.1523-1755.2000.00965.x","article-title":"Mineralocorticoid receptor knockout mice: lessons on Na+ metabolism","volume":"57","author":"Berger","year":"2000","journal-title":"Kidney Int."},{"key":"2021120120460888400_B60","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1161\/01.CIR.0000142858.44680.27","article-title":"Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice","volume":"110","author":"Garnier","year":"2004","journal-title":"Circulation"},{"key":"2021120120460888400_B61","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1161\/CIRCULATIONAHA.104.503706","article-title":"Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias","volume":"111","author":"Ouvrard-Pascaud","year":"2005","journal-title":"Circulation"},{"key":"2021120120460888400_B62","doi-asserted-by":"crossref","first-page":"7160","DOI":"10.1073\/pnas.102673599","article-title":"Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes","volume":"99","author":"Beggah","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021120120460888400_B63","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1161\/01.HYP.0000249902.09036.e7","article-title":"Disturbed homeostasis in sodium-restricted mice heterozygous and homozygous for aldosterone synthase gene disruption","volume":"48","author":"Makhanova","year":"2006","journal-title":"Hypertension"},{"key":"2021120120460888400_B64","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1210\/en.2002-220956","article-title":"Aldosterone inhibits inducible nitric oxide synthase in neonatal rat cardiomyocytes","volume":"144","author":"Chun","year":"2003","journal-title":"Endocrinology"},{"key":"2021120120460888400_B65","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000081267","article-title":"Effects of eplerenone, a selective aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy","volume":"73","author":"Wahed","year":"2005","journal-title":"Pharmacology"},{"key":"2021120120460888400_B66","doi-asserted-by":"crossref","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","article-title":"Aldosterone induces a vascular inflammatory phenotype in the rat heart","volume":"283","author":"Rocha","year":"2002","journal-title":"Am. J. Physiol. Heart Circ. Physiol"},{"key":"2021120120460888400_B67","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/j.1523-1755.2004.00913.x","article-title":"Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats","volume":"66","author":"Fujisawa","year":"2004","journal-title":"Kidney Int."},{"key":"2021120120460888400_B68","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1681\/ASN.2005121375","article-title":"Involvements of rho-kinase and TGF-\u03b2 pathways in aldosterone-induced renal injury","volume":"17","author":"Sun","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021120120460888400_B69","doi-asserted-by":"crossref","first-page":"F1059","DOI":"10.1152\/ajprenal.00202.2003","article-title":"Effect of aldosterone on renal transforming growth factor-\u03b2","volume":"286","author":"Juknevicius","year":"2004","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"2021120120460888400_B70","first-page":"F563","article-title":"Early role of Fsp1 in epithelial-mesenchymal transformation","volume":"273","author":"Okada","year":"1997","journal-title":"Am. J. Physiol."},{"key":"2021120120460888400_B71","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0002-9440(10)63486-4","article-title":"Transforming growth factor-\u03b2-dependent and -independent pathways of induction of tubulointerstitial fibrosis in \u03b26\u2212\/\u2212 mice","volume":"163","author":"Ma","year":"2003","journal-title":"Am. J. Pathol."},{"key":"2021120120460888400_B72","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1093\/emboj\/17.11.3091","article-title":"Direct binding of Smad3 and Smad4 to critical TGF\u03b2-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene","volume":"17","author":"Dennler","year":"1998","journal-title":"EMBO J."},{"key":"2021120120460888400_B73","first-page":"336","article-title":"Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production","volume":"85","author":"Brown","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021120120460888400_B74","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.mce.2005.03.016","article-title":"Aldosterone increases plasminogen activator inhibitor-1 synthesis in rat cardiomyocytes","volume":"239","author":"Chun","year":"2005","journal-title":"Mol. Cell. Endocrinol."},{"key":"2021120120460888400_B75","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1210\/en.2006-1438","article-title":"Early aldosterone-regulated genes in cardiomyocytes: clues to cardiac remodeling?","volume":"148","author":"Fejes-Toth","year":"2007","journal-title":"Endocrinology"},{"key":"2021120120460888400_B76","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.2174\/0929867043364595","article-title":"Plasminogen activator inhibitor-1","volume":"11","author":"Gils","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"2021120120460888400_B77","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/01.CIR.0000097000.51723.6F","article-title":"Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II\/NG-nitro-L-arginine methyl ester-induced myocardial injury","volume":"108","author":"Oestreicher","year":"2003","journal-title":"Circulation"},{"key":"2021120120460888400_B78","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1681\/ASN.2004090804","article-title":"Regression of existing glomerulosclerosis by inhibition of aldosterone","volume":"16","author":"Aldigier","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021120120460888400_B79","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1161\/01.ATV.0000152356.85791.52","article-title":"Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II\/salt-induced aortic remodeling","volume":"25","author":"Weisberg","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021120120460888400_B80","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/sj.ki.5000201","article-title":"Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury","volume":"69","author":"Ma","year":"2006","journal-title":"Kidney Int."},{"key":"2021120120460888400_B81","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1083\/jcb.110.3.767","article-title":"Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity","volume":"110","author":"Saksela","year":"1990","journal-title":"J. Cell Biol."},{"key":"2021120120460888400_B82","doi-asserted-by":"crossref","first-page":"26031","DOI":"10.1016\/S0021-9258(18)35712-0","article-title":"Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms","volume":"267","author":"Houck","year":"1992","journal-title":"J. Biol. Chem."},{"key":"2021120120460888400_B83","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1161\/01.RES.0000141427.61023.f4","article-title":"Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type\u00a01 causes cardiac fibrosis in mice","volume":"95","author":"Moriwaki","year":"2004","journal-title":"Circ. Res."},{"key":"2021120120460888400_B84","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0895-7061(01)02291-9","article-title":"Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1","volume":"15","author":"Park","year":"2002","journal-title":"Am. J. Hypertens."},{"key":"2021120120460888400_B85","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1210\/en.2006-0965","article-title":"A direct effect of aldosterone on endothelin-1 gene expression in vivo","volume":"148","author":"Wong","year":"2007","journal-title":"Endocrinology"},{"key":"2021120120460888400_B86","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1093\/cvr\/27.12.2130","article-title":"Effects of endothelins on collagen turnover in cardiac fibroblasts","volume":"27","author":"Guarda","year":"1993","journal-title":"Cardiovasc. Res."},{"key":"2021120120460888400_B87","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1097\/00005344-200206000-00015","article-title":"Endothelin A receptor blockade decreases expression of growth factors and collagen and improves matrix metalloproteinase-2 activity in kidneys from stroke-prone spontaneously hypertensive rats","volume":"39","author":"Tostes","year":"2002","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"2021120120460888400_B88","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1161\/01.HYP.0000078357.92682.EC","article-title":"Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling","volume":"42","author":"Pu","year":"2003","journal-title":"Hypertension."},{"key":"2021120120460888400_B89","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"2021120120460888400_B90","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"2021120120460888400_B91","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0002-9149(00)00729-3","article-title":"Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy","volume":"85","author":"Ramires","year":"2000","journal-title":"Am. J. Cardiol."},{"key":"2021120120460888400_B92","first-page":"471","article-title":"Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure","volume":"33","author":"Merlet","year":"1992","journal-title":"J. Nucl. Med."},{"key":"2021120120460888400_B93","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1210\/en.2005-1167","article-title":"Spironolactone preserves cardiac norepinephrine reuptake in salt-sensitive Dahl rats","volume":"147","author":"Buss","year":"2006","journal-title":"Endocrinology"},{"key":"2021120120460888400_B94","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","article-title":"Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES)","volume":"102","author":"Zannad","year":"2000","journal-title":"Circulation"},{"key":"2021120120460888400_B95","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","article-title":"Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study","volume":"108","author":"Pitt","year":"2003","journal-title":"Circulation"},{"key":"2021120120460888400_B96","first-page":"3","article-title":"Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome","volume":"45","author":"Conn","year":"1955","journal-title":"J. Lab. Clin. Med."},{"key":"2021120120460888400_B97","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","article-title":"Hyperaldosteronism among black and white subjects with resistant hypertension","volume":"40","author":"Calhoun","year":"2002","journal-title":"Hypertension"},{"key":"2021120120460888400_B98","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1378\/chest.125.1.112","article-title":"Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea","volume":"125","author":"Calhoun","year":"2004","journal-title":"Chest"},{"key":"2021120120460888400_B99","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1055\/s-2007-970409","article-title":"Detecting and treating primary aldosteronism: primary aldosteronism","volume":"115","author":"Mantero","year":"2007","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"2021120120460888400_B100","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","article-title":"Effect of spironolactone on blood pressure in subjects with resistant hypertension","volume":"49","author":"Chapman","year":"2007","journal-title":"Hypertension"},{"key":"2021120120460888400_B101","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1161\/01.HYP.0000174327.53863.86","article-title":"Differing effects of mineralocorticoid receptor-dependent and -independent potassium-sparing diuretics on fibrinolytic balance","volume":"46","author":"Ma","year":"2005","journal-title":"Hypertension"},{"key":"2021120120460888400_B102","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/ajkd.2001.22069","article-title":"Late escape from the antiproteinuric effect of ace inhibitors in nondiabetic renal disease","volume":"37","author":"Shiigai","year":"2001","journal-title":"Am. J. Kidney Dis."},{"key":"2021120120460888400_B103","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","article-title":"Effectiveness of aldosterone blockade in patients with diabetic nephropathy","volume":"41","author":"Sato","year":"2003","journal-title":"Hypertension"},{"key":"2021120120460888400_B104","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jama.286.4.421","article-title":"Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals","volume":"286","author":"Gerstein","year":"2001","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"2021120120460888400_B105","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.amjcard.2004.01.007","article-title":"Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension","volume":"93","author":"Williams","year":"2004","journal-title":"Am. J. Cardiol."},{"key":"2021120120460888400_B106","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1161\/01.HYP.0000067463.13172.EA","article-title":"Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension","volume":"41","author":"White","year":"2003","journal-title":"Hypertension"},{"key":"2021120120460888400_B107","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1464-5491.2004.01194.x","article-title":"The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study","volume":"21","author":"Rachmani","year":"2004","journal-title":"Diabetic Med."},{"key":"2021120120460888400_B108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-5273(01)00483-1","article-title":"Exciting new drugs on the horizon: eplerenone, a selective aldosterone receptor antagonist (SARA)","volume":"80","author":"Coats","year":"2001","journal-title":"Int. J. Cardiol."},{"key":"2021120120460888400_B109","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.amjhyper.2004.06.029","article-title":"Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease","volume":"18","author":"Sato","year":"2005","journal-title":"Am. J. Hypertens."},{"key":"2021120120460888400_B110","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1053\/j.ajkd.2005.03.007","article-title":"Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study","volume":"46","author":"Bianchi","year":"2005","journal-title":"Am. J. Kidney Dis."},{"key":"2021120120460888400_B111","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1161\/01.HYP.0000231338.41548.fc","article-title":"Plasma aldosterone is independently associated with the metabolic syndrome","volume":"48","author":"Bochud","year":"2006","journal-title":"Hypertension"},{"key":"2021120120460888400_B112","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/01.HYP.0000253258.36141.c7","article-title":"Association of adrenal steroids with hypertension and the metabolic syndrome in blacks","volume":"49","author":"Kidambi","year":"2007","journal-title":"Hypertension"},{"key":"2021120120460888400_B113","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1161\/01.HYP.25.1.30","article-title":"Relationships among plasma aldosterone, high-density lipoprotein cholesterol, and insulin in humans","volume":"25","author":"Goodfriend","year":"1995","journal-title":"Hypertension"},{"key":"2021120120460888400_B114","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/j.1550-8528.1999.tb00418.x","article-title":"Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women","volume":"7","author":"Goodfriend","year":"1999","journal-title":"Obes. Res."},{"key":"2021120120460888400_B115","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1161\/01.HYP.0000113294.06704.64","article-title":"Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion","volume":"43","author":"Goodfriend","year":"2004","journal-title":"Hypertension"},{"key":"2021120120460888400_B116","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.2165\/00003495-200464220-00004","article-title":"Prevention of type\u00a02 diabetes mellitus through inhibition of the renin-angiotensin system","volume":"64","author":"Scheen","year":"2004","journal-title":"Drugs"},{"key":"2021120120460888400_B117","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF00456122","article-title":"Effect of adrenal steroids on insulin release from cultured rat islets of Langerhans","volume":"29","author":"Pierluissi","year":"1986","journal-title":"Diabetologia"},{"key":"2021120120460888400_B118","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2337\/diab.23.12.933","article-title":"Cationic environment and dynamics of insulin secretion. II. Effect of a high concentration of potassium","volume":"23","author":"Henquin","year":"1974","journal-title":"Diabetes"},{"key":"2021120120460888400_B119","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0960-0760(99)00117-X","article-title":"Inhibition by aldosterone of insulin receptor mRNA levels and insulin binding in U-937 human promonocytic cells","volume":"70","author":"Campion","year":"1999","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"2021120120460888400_B120","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1507\/endocrj.51.243","article-title":"Aldosterone stimulates gene expression of hepatic gluconeogenic enzymes through the glucocorticoid receptor in a manner independent of the protein kinase B cascade","volume":"51","author":"Yamashita","year":"2004","journal-title":"Endocr. J."},{"key":"2021120120460888400_B121","doi-asserted-by":"crossref","first-page":"F1264","DOI":"10.1152\/ajprenal.00299.2005","article-title":"Resistance of mice lacking the serum- and glucocorticoid-inducible kinase SGK1 against salt-sensitive hypertension induced by a high-fat diet","volume":"291","author":"Huang","year":"2006","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"2021120120460888400_B122","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1056\/NEJM196511182732106","article-title":"Hypertension, the potassium ion and impaired carbohydrate tolerance","volume":"273","author":"Conn","year":"1965","journal-title":"N. Engl. J. Med."},{"key":"2021120120460888400_B123","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1210\/jc.2006-0736","article-title":"Insulin sensitivity in patients with primary aldosteronism: a follow-up study","volume":"91","author":"Catena","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021120120460888400_B124","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/HJH.0b013e3280108e6f","article-title":"Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study","volume":"25","author":"Giacchetti","year":"2007","journal-title":"J. Hypertens."},{"key":"2021120120460888400_B125","first-page":"21","article-title":"Insulin action in primary hyperaldosteronism before and after surgical or pharmacological treatment","volume":"108","author":"Sindelka","year":"2000","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"2021120120460888400_B126","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study","volume":"28","author":"Rossing","year":"2005","journal-title":"Diabetes Care"},{"key":"2021120120460888400_B127","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.metabol.2006.07.025","article-title":"The effect of spironolactone on circulating adipocytokines in patients with type\u00a02 diabetes mellitus complicated by diabetic nephropathy","volume":"55","author":"Matsumoto","year":"2006","journal-title":"Metab., Clin. Exp."},{"key":"2021120120460888400_B128","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1152\/advan.00051.2001","article-title":"Aldosterone","volume":"26","author":"Booth","year":"2002","journal-title":"Adv. Physiol. Educ."},{"key":"2021120120460888400_B129","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1161\/01.HYP.0000034738.79310.06","article-title":"Spironolactone improves angiotensin-induced vascular changes and oxidative stress","volume":"40","author":"Virdis","year":"2002","journal-title":"Hypertension"},{"key":"2021120120460888400_B130","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1161\/01.CIR.0000127949.05756.9D","article-title":"Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone","volume":"109","author":"Keidar","year":"2004","journal-title":"Circulation"}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/113\/6\/267\/438181\/cs1130267.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/113\/6\/267\/438181\/cs1130267.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T16:30:47Z","timestamp":1638376247000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/113\/6\/267\/68332\/Aldosterone-and-end-organ-damage"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,13]]},"references-count":130,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,9,1]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20070123","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1089245.542445","asserted-by":"object"}]},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,13]]}}}